CONFIRM anti-CD20 (L26) Primary Antibody

REF 760-2531

05267099001

IVD Σ 50



Figure 1. CONFIRM anti-CD20 (L26) Primary Antibody staining of appendix using OptiView DAB IHC Detection Kit.

INTENDED USE

CONFIRM anti-CD20 (L26) Primary Antibody is intended for laboratory use in the qualitative immunohistochemical detection of CD20 by light microscopy in sections of formalin-fixed, paraffin-embedded tissue stained on a BenchMark IHC/ISH instrument.

This product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.

This antibody is intended for *in vitro* diagnostic (IVD) use.

SUMMARY AND EXPLANATION

CONFIRM anti-CD20 (L26) Primary Antibody (CONFIRM anti-CD20 (L26) antibody) is a mouse monoclonal antibody produced against the CD20 antigen. CD20 is a 33-36 kDa non-glycosylated transmembrane protein that is expressed on B lineage cells.[1-6] Expression is first noted in the pre-B cell stage and continues throughout all stages of B-cell maturation.[3-8] However, this antigen is not expressed on pro-B cells or plasma cells.[3-8] CD20 is the most commonly used pan B-cell marker for assessment of B-cell lineages and is expressed in almost all mature B-cell neoplasms and almost no T-cells.[3-8] Of note, detection of or expression of CD20 within a tissue specimen may diminish in patients treated with anti-CD20 targeted therapies.[9,10] Therefore, under these circumstances, confirmation of B-cell lineage would rely on other pan-B cell markers such as CD19, CD79a, or Pax5, the expression of which is not affected by anti-CD20 therapeutics.[9,10]

The detection of CD20 by immunohistochemistry (IHC) with CONFIRM anti-CD20 (L26) antibody may be used to aid in the identification of normal and neoplastic B-cells. It may be used as part of a panel of IHC studies. The staining pattern is membranous.

PRINCIPLE OF THE PROCEDURE

CONFIRM anti-CD20 (L26) antibody may be used as the primary antibody for immunohistochemical staining of paraffin tissue sections. CONFIRM anti-CD20 (L26) antibody binds to CD20 protein in formalin-fixed, paraffin-embedded (FFPE) tissue sections and exhibits a membranous staining pattern. CONFIRM anti-CD20 (L26) antibody can be visualized using OptiView DAB IHC Detection Kit (Cat. No. 760-700 / 06396500001) or *ultra*View Universal DAB Detection Kit (Cat. No. 760-500 / 05269806001). Refer to the respective method sheet for further information.

MATERIAL PROVIDED

CONFIRM anti-CD20 (L26) antibody contains sufficient reagent for 50 tests.

One 5 mL dispenser of CONFIRM anti-CD20 (L26) antibody contains approximately 1.5 µg of a mouse monoclonal (L26) antibody.

The antibody is diluted in Tris-HCl with carrier protein and 0.10% ProClin 300, a preservative.

Specific antibody concentration is approximately 0.3 µg/mL. There is no known non-specific antibody reactivity observed for this product.

CONFIRM anti-CD20 (L26) antibody is a mouse monoclonal antibody produced as a cell culture supernatant.

Refer to the appropriate VENTANA detection kit method sheet for detailed descriptions of: Principle of the Procedure, Material and Methods, Specimen Collection and Preparation for Analysis, Quality Control Procedures, Troubleshooting, Interpretation of Results, and Limitations.

MATERIALS REQUIRED BUT NOT PROVIDED

Staining reagents, such as VENTANA detection kits and ancillary components, including negative and positive tissue control slides, are not provided.

Not all products listed in the method sheet may be available in all geographies. Consult your local support representative.

The following reagents and materials may be required for staining but are not provided:

1. Recommended control tissue
2. Microscope slides, positively charged
3. Negative Control (Monoclonal) (Cat. No. 760-2014 / 05266670001)
4. OptiView DAB IHC Detection Kit (Cat. No. 760-700 / 06396500001)
5. *ultra*View Universal DAB Detection Kit (Cat. No. 760-500 / 05269806001)
6. EZ Prep Concentrate (10X) (Cat. No. 950-102 / 05279771001)
7. Reaction Buffer Concentrate (10X) (Cat. No. 950-300 / 05353955001)
8. LCS (Predilute) (Cat. No. 650-010 / 05264839001)
9. ULTRA LCS (Predilute) (Cat. No. 650-210 / 05424534001)
10. Cell Conditioning Solution (CC1) (Cat. No. 950-124 / 05279801001)
11. ULTRA Cell Conditioning Solution (ULTRA CC1) (Cat. No. 950-224 / 05424569001)
12. Hematoxylin II (Cat. No. 790-2208 / 05277965001)
13. Bluing Reagent (Cat. No. 760-2037 / 05266769001)
14. Permanent mounting medium
15. Cover glass
16. Automated coverslipper
17. General purpose laboratory equipment
18. BenchMark IHC/ISH instrument

STORAGE AND STABILITY

Upon receipt and when not in use, store at 2-8°C. Do not freeze.

To ensure proper reagent delivery and stability of the antibody, replace the dispenser cap after every use and immediately place the dispenser in the refrigerator in an upright position.

Every antibody dispenser is expiration dated. When properly stored, the reagent is stable to the date indicated on the label. Do not use reagent beyond the expiration date.

SPECIMEN PREPARATION

Routinely processed FFPE tissues are suitable for use with this primary antibody when used with VENTANA detection kits and BenchMark IHC/ISH instruments. The recommended tissue fixative is 10% neutral buffered formalin.[11] Sections should be cut at approximately 4 µm in thickness and mounted on positively charged slides. Slides should be stained immediately, as antigenicity of cut tissue sections may diminish over time. Ask your Roche representative for a copy of "Recommended Slide Storage and Handling" for more information.

It is recommended that positive and negative controls be run simultaneously with unknown specimens.

WARNINGS AND PRECAUTIONS

1. For in vitro diagnostic (IVD) use.
2. For professional use only.
3. **CAUTION**: In the United States, Federal law restricts this device to sale by or on the order of a physician. (Rx Only)
4. Do not use beyond the specified number of tests.
5. ProClin 300 solution is used as a preservative in this reagent. It is classified as an irritant and may cause sensitization through skin contact. Take reasonable precautions when handling. Avoid contact of reagents with eyes, skin, and mucous membranes. Use protective clothing and gloves.
6. Positively charged slides may be susceptible to environmental stresses resulting in inappropriate staining Ask your Roche representative for more information on how to use these types of slides.
7. Materials of human or animal origin should be handled as biohazardous materials and disposed of with proper precautions. In the event of exposure, the health directives of the responsible authorities should be followed.[12,13]
8. Avoid contact of reagents with eyes and mucous membranes. If reagents come in contact with sensitive areas, wash with copious amounts of water.
9. Avoid microbial contamination of reagents as it may cause incorrect results.

10. For further information on the use of this device, refer to the BenchMark IHC/ISH instrument User Guide, and instructions for use of all necessary components located at navifyportal.roche.com.
11. Consult local and/or state authorities with regard to recommended method of disposal.
12. Product safety labeling primarily follows EU GHS guidance. Safety data sheet available for professional user on request.
13. To report suspected serious incidents related to this device, contact the local Roche representative and the competent authority of the Member State or Country in which the user is established.

This antibody contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008

Table 1. Hazard information.

Hazard	Code	Statement
Warning 	H317	May cause an allergic skin reaction.
	H412	Harmful to aquatic life with long lasting effects.
	P261	Avoid breathing mist or vapours.
	P273	Avoid release to the environment.
	P280	Wear protective gloves.
	P333 + P313	If skin irritation or rash occurs: Get medical advice/ attention.
	P362 + P364	Take off contaminated clothing and wash it before reuse.
	P501	Dispose of contents/ container to an approved waste disposal plant.

This product contains CAS # 55965-84-9, reaction mass of: 5-chloro-2-methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (3:1).

STAINING PROCEDURE

VENTANA primary antibodies have been developed for use on BenchMark IHC/ISH instruments in combination with VENTANA detection kits and accessories. Refer to Table 2 and Table 3 for recommended staining protocols.

CONFIRM anti-CD20 (L26) antibody has been optimized for specific incubation and antigen retrieval times but the user must validate results obtained with this reagent. It is highly recommended that the user does not omit the cell conditioning step.

The parameters for the automated procedures can be displayed, printed and edited according to the procedure in the instrument User Guide. Refer to the appropriate VENTANA detection kit method sheet for more details regarding immunohistochemistry staining procedures.

For more details on the proper use of this device, refer to the inline dispenser method sheet associated with P/N 760-2531.

Table 2. Recommended staining protocol for CONFIRM anti-CD20 (L26) antibody with OptiView DAB IHC Detection Kit on BenchMark IHC/ISH instruments.

Procedure Type	Method		
	GX	XT	ULTRA or ULTRA PLUS [a]
Deparaffinization	Selected	Selected	Selected
Cell Conditioning (Antigen Unmasking)	CC1 32 minutes	CC1 24 minutes	ULTRA CC1 32 minutes, 100°C
Pre-Primary Peroxidase Inhibitor	Selected	Selected	Selected
Antibody (Primary)	6 minutes, 37°C	16 minutes, 37°C	16 minutes, 36°C
OptiView HQ Linker	8 minutes (default)		
OptiView HRP Multimer	8 minutes (default)		
Counterstain	Hematoxylin II, 4 minutes		
Post Counterstain	Bluing, 4 minutes		

[a] Concordance was demonstrated between BenchMark ULTRA and BenchMark ULTRA PLUS instruments using representative assays.

Table 3. Recommended staining protocol for CONFIRM anti-CD20 (L26) antibody with *ultra*View Universal DAB Detection Kit on BenchMark IHC/ISH instruments.

Procedure Type	Method		
	GX	XT	ULTRA or ULTRA PLUS [a]
Deparaffinization	Selected	Selected	Selected
Cell Conditioning (Antigen Unmasking)	CC1 Mild	CC1 Mild	ULTRA CC1 36 min, 95°C
Antibody (Primary)	8 minutes, 37°C	16 minutes, 37°C	16 minutes, 36°C
Counterstain	Hematoxylin II, 4 minutes		
Post Counterstain	Bluing, 4 minutes		

[a] Concordance was demonstrated between BenchMark ULTRA and BenchMark ULTRA PLUS instruments using representative assays.

Due to variation in tissue fixation and processing, as well as general lab instrument and environmental conditions, it may be necessary to increase or decrease the primary antibody incubation, cell conditioning or protease pretreatment based on individual specimens, detection used, and reader preference. For further information on fixation variables, refer to "Immunohistochemistry Principles and Advances."[14]

NEGATIVE REAGENT CONTROL

In addition to staining with anti-CD20 (L26) antibody, a second slide should be stained with the appropriate negative control reagent.

POSITIVE TISSUE CONTROL

Optimal laboratory practice is to include a positive control section on the same slide as the test tissue. This helps identify any failures applying reagents to the slide. Tissue with weak positive staining is best suited for quality control. Control tissue may contain both positive and negative staining elements and serve as both the positive and negative control. Control tissue should be fresh autopsy, biopsy, or surgical specimen, prepared or fixed as soon as possible in a manner identical to test sections.

Known positive tissue controls should be utilized only for monitoring performance of reagents and instruments, not as an aid in determining specific diagnosis of test samples. If the positive tissue controls fail to demonstrate positive staining, results of the test specimen should be considered invalid.

Examples of positive control tissues for CONFIRM anti-CD20 (L26) antibody are spleen, tonsil, or lymph node.

STAINING INTERPRETATION / EXPECTED RESULTS

The cellular staining pattern for CONFIRM anti-CD20 (L26) antibody is membranous.

SPECIFIC LIMITATIONS

OptiView Detection is generally more sensitive than *ultra*View Detection system. The user must validate results obtained with this reagent and detection systems.

All assays might not be registered on every instrument. Please contact your local Roche representative for more information.

PERFORMANCE CHARACTERISTICS

ANALYTICAL PERFORMANCE

Staining tests for sensitivity, specificity, and precision were conducted and the results are listed below.

Sensitivity and Specificity

Table 4. Sensitivity/Specificity of CONFIRM anti-CD20 (L26) antibody was determined by testing FFPE normal tissues.

Tissue	# positive / total cases	Tissue	# positive / total cases
Cerebrum	0/3	Thymus*	0/3
Cerebellum	0/3	Myeloid (Bone marrow)*	0/3
Adrenal gland	0/3	Lung*	0/3
Ovary	0/3	Heart	0/3
Pancreas*	0/3	Esophagus*	0/3
Parathyroid gland*	0/3	Stomach*	0/3
Pituitary Gland*	0/3	Small intestine*	0/3
Testis	0/3	Colon*	0/3
Thyroid*	0/3	Liver*	0/3
Breast*	0/5	Salivary gland*	0/3
Spleen*	5/5	Kidney*	0/3
Tonsil*	7/7	Prostate*	0/3
Endometrium*	0/3	Cervix*	0/3
Skeletal muscle	0/3	Skin*	0/3
Nerve (sparse)	0/3	Mesothelium of lung	0/6
Bladder*	0/4	Lymph node*	7/7

* B lymphocytes staining

Table 5. Sensitivity/Specificity of CONFIRM anti-CD20 (L26) antibody was determined in verification by testing a variety of FFPE neoplastic tissues.

Pathology	# positive / total cases
Glioblastoma (Cerebrum)	0/1
Meningioma (Cerebrum)	0/1
Ependymoma (Cerebrum)	0/1
Oligodendroglioma (Cerebrum)	0/1
Serous papillary carcinoma (Ovary)	0/1
Carcinoma (Ovary)	0/1
Neuroendocrine neoplasm (Pancreas)	0/1
Adenocarcinoma (Pancreas)	0/1
Seminoma (Testis)	0/2
Medullary carcinoma (Thyroid)	0/1
Papillary carcinoma (Thyroid)	0/1
Ductal carcinoma in situ (DCIS) (Breast)	0/2
Invasive ductal carcinoma (Breast)	0/1
Small cell carcinoma (Lung)	0/1
Squamous cell carcinoma (Lung)	0/1
Adenocarcinoma (Lung)	0/1
Neuroendocrine carcinoma (Esophagus)	0/1
Adenocarcinoma (Esophagus)	0/1
Signet-ring cell carcinoma (Stomach)	0/1
Adenocarcinoma (Gastrointestinal)	0/3
Gastrointestinal stromal tumor (GIST)	0/3
Hepatocellular carcinoma (Liver)	0/1
Hepatoblastoma (Liver)	0/1
Clear cell carcinoma (Kidney)	0/1
Adenocarcinoma (Prostate)	0/2
Carcinoma (Endometrium)	0/1
Clear cell carcinoma (Endometrium)	0/1
Squamous cell carcinoma (Cervix)	0/2
Embryonal rhabdomyosarcoma	0/1
Melanoma (Rectum)	0/1
Basal cell carcinoma (Skin)	0/1
Squamous cell carcinoma (Skin)	0/1
Neurofibroma	0/1
Neuroblastoma (Retroperitoneal)	0/1
Mesothelioma	0/1
Urothelial carcinoma (Bladder)	0/1
Leiomyosarcoma	0/2
Osteosarcoma	0/1
Spindle cell rhabdomyosarcoma	0/1
B-cell lymphoma, NOS	129/133
T-cell lymphoma, NOS	1/54
Anaplastic large cell lymphoma (Lymph node)	1/5
Hodgkin lymphoma (Lymph node)	1/3

Precision

Precision studies for CONFIRM anti-CD20 (L26) antibody were completed to demonstrate:

- Between-lot intermediate precision of the antibody.
- Within-run and Between-day precision on a BenchMark ULTRA instrument.
- Between-instrument intermediate precision on the BenchMark GX, BenchMark XT, and BenchMark ULTRA instrument.

- Between-platform intermediate precision between the BenchMark GX, BenchMark XT, and BenchMark ULTRA instrument.

All studies met their acceptance criteria.

Precision on the BenchMark ULTRA PLUS instrument was demonstrated using representative assays. Studies included Within-run Repeatability, Between-day and Between-Instrument Intermediate Precision. All studies met their acceptance criteria.

CLINICAL PERFORMANCE

Clinical performance data relevant to the intended purpose of CONFIRM anti-CD20 (L26) antibody were assessed by systematic review of the literature. The data gathered support the use of the device in accordance with its intended purpose.

REFERENCES

1. Mason DY, Comans-Bitter WM, Cordell JL, Verhoeven MA, van Dongen JJm . Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol. 1990;136(6):1215-1222.
2. Chu PG, Loera S, Huang Q, Weiss LM. Lineage determination of CD20-B-Cell neoplasms: an immunohistochemical study. Am J Clin Pathol. 2006;126(4):534-544.
3. Swerdlow S, Campo E, Harris NL, et al. Who Classification of Tumours. Lyon: IARC; 2017.
4. O'Malley DP, Fedoriw Y, Grimm KE, et al. Immunohistology of Lymph Node and Lymph Node Neoplasms, 5th Edition. In: Dabbs DJ, ed. Diagnostic Immunohistochemistry. Elsevier 2019:160-202
5. Higgins RA, Blankenship JE, Kinney MC. Application of Immunohistochemistry in the Diagnosis of Non-Hodgkin and Hodgkin Lymphoma. Arch Pathol Lab Med. 2008;132(3):441-461.
6. O'Malley DP, Auerbach A, Weiss LM. Practical Applications in Immunohistochemistry: Evaluation of Diffuse Large B-Cell Lymphoma and Related Large B-Cell Lymphomas. Arch Pathol Lab Med. 2015;139(9):1094-1107
7. Bene MC, Nebe T, Bettelheim P, et al. Immunophenotyping of Acute Leukemia and Lymphoproliferative Disorders: A Consensus Proposal of the European Leukemianet Work Package 10. Leukemia. 2011;25(4):567-574.
8. Buske C, Hutchings M, Ladetto M, et al. ESMO Consensus Conference on Malignant Lymphoma: General Perspectives and Recommendations for the Clinical Management of the Elderly Patient with Malignant Lymphoma. Ann Oncol. 2018;29(3):544-562.
9. Cragg MS, Walshe CA, Ivanov AO, et al. The Biology of CD20 and Its Potential as a Target for Mab Therapy. In: Stohl W, ed. B Cell Trophic Factors and B Cell Antagonism in Autoimmune Disease. Vol 8. Basel, Karger 2005:140-174
10. Casan JML, Wong J, Northcott MJ, et al. Anti-CD20 Monoclonal Antibodies: Reviewing a Revolution. Hum Vaccin Immunother. 2018;14(12):2820-2841.
11. Carson FL, Cappellano C. HIstotechnology; A Self-Instructional Text, 5th edition. American Society for Clinical Pathology Press; 2020, 2022.
12. Occupational Safety and Health Standards: Occupational exposure to hazardous chemicals in laboratories. (29 CFR Part 1910.1450). Fed. Register.
13. Directive 2000/54/EC of the European Parliament and Council of 24 June 2020 on the protection of workers from risks related to exposure to biological agents at work.
14. Roche PC, Hsi ED. Immunohistochemistry-Principles and Advances. Manual of Clinical Laboratory Immunology, 6th edition. (NR Rose Ed.) ASM Press, 2002.

NOTE: A point (period/stop) is always used in this document as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

The summary of safety and performance can be found here:

https://ec.europa.eu/tools/eudamed

Symbols

Ventana uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see elabdoc.roche.com/symbols for more information).

GTIN	Global Trade Item Number
UDI	Unique Device Identification
	Indicates the entity importing the medical device into the European Union

REVISION HISTORY

Rev	Updates
H	Updates to Analytical Performance section.

INTELLECTUAL PROPERTY

CONTACT INFORMATION

Ventana Medical Systems, Inc.
1910 E. Innovation Park Drive
Tucson, Arizona 85755
USA
+1 520 887 2155
+1 800 227 2155 (USA)

www.roche.com

EC REP

Roche Diagnostics GmbH
Sandhofer Strasse 116
D-68305 Mannheim
Germany
+800 5505 6606

CE 0123